Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database

不良事件报告系统 医学 药物警戒 优势比 内科学 不利影响 数据库 肿瘤科 计算机科学
作者
Wensheng Liu,Qiong Du,Zihan Guo,Xuan Ye,Jiyong Liu
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:14 被引量:7
标识
DOI:10.3389/fphar.2023.1283247
摘要

Background and objective: Sacituzumab govitecan (SG), the first antibody-drug conjugate targeting human trophoblast cell-surface antigen 2 (Trop-2), has been approved by the Food and Drug Administration (FDA) for the treatment of advanced or metastatic breast cancer and urothelial cancer. However, there is currently a dearth of information regarding the safety profiles of SG in a large sample cohort. The objective of the present study is to investigate SG-related adverse events (AEs) in real-world settings leveraging the FDA Adverse Event Reporting System (FAERS) database to guide the safety management of clinical medication. Methods: The FAERS database was retrospectively queried to extract reports associated with SG from April 2020 to March 2023. To identify and evaluate potential AEs in patients receiving SG, various disproportionality analyses such as reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) were employed. Results: Overall, 2069 reports of SG as the "primary suspect" were identified. Noteworthy, SG was significantly associated with an increased risk of blood lymphatic system disorders (ROR, 7.18; 95% CI, 6.58-7.84) and hepatobiliary disorders (ROR, 2.68; 95% CI, 2.17-3.30) at the System Organ Class (SOC) level. Meanwhile, 61 significant disproportionality preferred terms (PTs) simultaneously complied with all four algorithms were adopted. Therein, anemia, thrombocytopenia, neutropenia, leukopenia, diarrhea, asthenia, alopecia, and electrolyte imbalance were consistent with the common AEs described in the clinical trials and specification of SG. Furthermore, unexpected significant AEs include colitis (ROR, 12.09; 95% CI, 9.1-16.08), heart rate increased (ROR, 5.11; 95% CI, 3.84-6.79), sepsis (ROR, 4.77; 95% CI, 3.59-6.34), cholestasis (ROR, 6.28; 95% CI, 3.48-11.36), blood bilirubin increased (ROR, 4.65; 95% CI, 2.42-8.94) and meningitis (ROR, 7.23; 95% CI, 2.71-19.29) were also be detected. The median time to onset of SG-related AEs was 14 [interquartile range (IQR), 7-52] days, with the majority occurring within the initial month of SG treatment. Conclusion: Our study validates the commonly known AEs and also found some potentially emerging safety issues related to SG in real-world clinical practice, which could provide valuable vigilance evidence for clinicians and pharmacists to manage the safety issues of SG.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
回首不再是少年完成签到,获得积分0
2秒前
4秒前
Singularity发布了新的文献求助20
7秒前
chenchen完成签到 ,获得积分10
8秒前
10秒前
含糊的盼波完成签到,获得积分10
11秒前
光亮如容完成签到,获得积分10
15秒前
15秒前
浩浩完成签到 ,获得积分0
18秒前
圆圆完成签到 ,获得积分10
30秒前
chunlily完成签到 ,获得积分10
30秒前
xujiahao完成签到,获得积分10
31秒前
32秒前
黑米粥发布了新的文献求助200
37秒前
37秒前
zw完成签到,获得积分10
38秒前
沉默岩完成签到,获得积分10
42秒前
中恐完成签到,获得积分0
42秒前
JamesPei的应助被shally采纳,获得10
43秒前
肥猫完成签到,获得积分10
47秒前
谦让的忆枫完成签到,获得积分10
47秒前
lll完成签到 ,获得积分10
48秒前
黑米粥发布了新的文献求助200
50秒前
arniu2008的应助被科研通管家采纳,获得20
52秒前
arniu2008的应助被科研通管家采纳,获得20
52秒前
arniu2008的应助被科研通管家采纳,获得20
52秒前
52秒前
开心完成签到 ,获得积分10
55秒前
shally发布了新的文献求助10
59秒前
Zzy完成签到 ,获得积分10
1分钟前
沙漏的回忆完成签到 ,获得积分10
1分钟前
zhao完成签到,获得积分10
1分钟前
1分钟前
starlx0813发布了新的文献求助50
1分钟前
黑米粥发布了新的文献求助200
1分钟前
Meera完成签到,获得积分10
1分钟前
拼搏忆文完成签到,获得积分10
1分钟前
慕青的应助被我要睡觉w采纳,获得10
1分钟前
科研顺利完成签到,获得积分10
1分钟前
深情安青的应助被dejavu采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185502
求助须知:如何正确求助?哪些是违规求助? 9574220
关于积分的说明 21834553
捐赠科研通 7783121
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558949
邀请新用户注册赠送积分活动 2481357